Microplastics and Nanomaterials: Understanding Emerging Contaminants in Environmental Testing

<p><strong>🎤Matthew Bolino</strong></p><p><strong>How do the hidden carbohydrate structures on your favorite protein powders shape the gut microbiome? &nbsp;In this episode of Concentrating on Chromatography, Matthew Bolino, M.S., from the University of Nevada, Reno, breaks down his latest research on N‑glycans from common dietary proteins (whey, egg white, soy, and pea) and how their structural diversity influences microbial fermentation and short‑chain fatty acid production.</strong></p><p>Bolino explains what N‑glycans are, why they behave like fiber in the gut, and how his team isolates and characterizes them using ethanol washes, enzymatic release (PNGase F and gut‑derived endoglycosidases), and advanced MALDI‑TOF and HILIC‑QTOF workflows. &nbsp;He also discusses his 2025 work comparing synthetic versus bovine whey N‑glycomes and mapping N‑glycan profiles across dietary protein sources, revealing how glycan architecture can reshape community diversity in in vitro fecal fermentations.</p><p>Geared toward undergraduate and early‑career analytical chemists, this conversation dives into practical mass spec trade‑offs (<strong>MALDI vs QTOF vs LC/GC</strong>), real‑world troubleshooting in glycomics labs, and how microbiome‑targeted therapeutics and “symbiotic” designs may emerge from pairing specific microbes with preferred glycan structures. &nbsp;Bolino closes with career advice on building biomolecular analysis skills, understanding instrumentation fundamentals, and entering the rapidly growing field of glycomics and microbiome research.</p><h3><strong>Video Transcription</strong></h3><h4><span><strong>Introduction</strong></span></h4><p>Glycomics has emerged as a rapidly developing field within biomolecular science, expanding our understanding of post-translational modifications beyond well-known processes such as phosphorylation. Among these modifications, <strong>protein glycosylation</strong>—the covalent attachment of carbohydrate structures to proteins—plays a critical role in biological function, molecular recognition, and cellular communication.</p><p>This discussion focuses on <strong>N-glycans</strong>, a class of structurally complex carbohydrates linked to proteins, and their occurrence in common dietary protein sources such as whey, egg white, soy, and pea protein. Particular emphasis is placed on their structural diversity, analytical workflows, and emerging relevance in gut microbiome research.</p><h4><span><strong>Fundamentals of N-Glycans</strong></span></h4><p>N-glycans are oligosaccharide structures covalently attached to proteins via nitrogen atoms, typically at asparagine residues. They represent one of the two major classes of protein glycosylation, alongside O-glycans.</p><p>These glycans are characterized by:</p><ul><li><strong>High structural diversity</strong>, arising from variations in monosaccharide composition and linkage patterns</li><li><strong>Large size</strong>, typically comprising 7–15 monosaccharide units</li><li><strong>Complex branching architectures</strong>, leading to a vast number of possible configurations</li></ul><p>Common monosaccharide components include:</p><ul><li>Mannose</li><li>Galactose</li><li>N-acetylglucosamine</li><li>N-acetylgalactosamine</li><li>Sialic acids</li></ul><p>Unlike free carbohydrates present in foods (e.g., glucose, lactose), N-glycans are <strong>protein-bound</strong>, which significantly influences their biological behavior.</p><h4><span><strong>Biological Function and Dietary Relevance</strong></span></h4><p>N-glycans play multiple roles in biological systems, including:</p><ul><li>Modulation of <strong>protein stability</strong></li><li>Regulation of <strong>protein trafficking and localization</strong></li><li>Facilitation of <strong>cell–cell communication and immune recognition</strong></li></ul><p>They are particularly abundant on <strong>membrane and surface proteins</strong>, where they contribute to molecular signaling processes.</p><p>From a dietary perspective, N-glycans exhibit unique behavior. Due to their size and protein-bound nature, they are not readily digested in the upper gastrointestinal tract. Instead, they can reach the colon, where they may function analogously to <strong>dietary fiber</strong>, interacting with the gut microbiota.</p><h4><span><strong>Research Motivation</strong></span></h4><p>The investigation of N-glycans in dietary proteins was initially driven by interest in protein nutrition and supplementation, particularly in the context of muscle growth and protein quality. However, this focus expanded upon recognition of the importance of glycosylation in biological systems.</p><p>The field of glycomics offers:</p><ul><li>Extensive <strong>structural variability</strong>, enabling diverse biological functions</li><li>Relevance in <strong>disease mechanisms</strong>, including cancer, where glycosylation patterns can influence immune evasion</li><li>Opportunities to explore <strong>diet–microbiome interactions</strong></li></ul><p>This combination of nutritional, biochemical, and biomedical relevance makes N-glycan research particularly compelling.</p><h4><span><strong>Experimental Workflow for N-Glycan Analysis</strong></span></h4><p>The analysis of N-glycans requires a multi-step workflow due to their covalent attachment to proteins.</p><h5><span><strong>1. Protein Purification</strong></span></h5><p>Dietary protein samples often contain:</p><ul><li>Free sugars</li><li>Lipids</li><li>Other matrix components</li></ul><p>To isolate glycoproteins:</p><ul><li><strong>Cold ethanol precipitation</strong> is used to remove free carbohydrates</li><li>Multiple washing steps ensure removal of residual sugars</li><li>A <strong>phenol–sulfuric acid assay</strong> is applied to confirm the absence of free sugars</li></ul><h5><span><strong>2. Enzymatic Release of N-Glycans</strong></span></h5><p>N-glycans are enzymatically cleaved from proteins using:</p><ul><li><strong>PNGase F (Peptide-N-Glycosidase F)</strong></li></ul><p>This enzyme:</p><ul><li>Specifically cleaves the glycan from the protein backbone</li><li>Preserves the intact glycan structure</li></ul><p>Alternative approaches using <strong>gut-derived enzymes</strong> are being explored to improve accessibility and yield.</p><h5><span><strong>3. Glycan Purification and Labeling</strong></span></h5><p>Following release:</p><ul><li>Glycans are purified from the protein matrix</li><li>Chemical labeling is performed (e.g., 2-AA or procainamide tagging)</li></ul><p>Labeling enhances:</p><ul><li>Detection sensitivity</li><li>Chromatographic behavior</li></ul><h5><span><strong>4. Analytical Techniques</strong></span></h5><p>Two primary analytical platforms are employed:</p><ul><li><strong>MALDI-TOF MS</strong><ul><li>High sensitivity</li><li>Broad structural coverage</li></ul></li><li><strong>HILIC-LC-MS</strong><ul><li>Improved reproducibility</li><li>Enhanced chromatographic separation</li></ul></li></ul><p>These approaches provide <strong>semi-quantitative data</strong>, where signal intensity reflects relative abundance rather than absolute concentration.</p><h4><span><strong>Analytical Challenges</strong></span></h4><p>Several challenges are associated with N-glycan analysis:</p><h5><span><strong>Low Abundance</strong></span></h5><ul><li>Dietary proteins typically contain only <strong>1–2% glycan content by weight</strong></li><li>This limits yield and complicates downstream applications</li></ul><h5><span><strong>Sample Preparation Complexity</strong></span></h5><ul><li>Extensive purification is required to eliminate free sugars</li><li>Contamination risks must be carefully managed</li></ul><h5><span><strong>Instrumentation Trade-Offs</strong></span></h5><ul><li>Different analytical platforms offer complementary advantages</li><li>No single technique provides complete structural and quantitative information</li></ul><h4><span><strong>Differences Between Plant and Animal N-Glycans</strong></span></h4><p>Comparative analysis reveals distinct differences in glycan composition:</p><h5><span><strong>Plant-Derived Proteins (e.g., soy, pea)</strong></span></h5><ul><li>Predominantly <strong>high-mannose structures</strong></li><li>Lower monosaccharide diversity</li><li>Simpler glycan architectures</li></ul><h5><span><strong>Animal-Derived Proteins (e.g., whey, egg white)</strong></span></h5><ul><li>Greater <strong>structural complexity</strong></li><li>Inclusion of diverse monosaccharides (e.g., sialic acids)</li><li>More elaborate branching patterns</li></ul><p>These differences have important implications for biological function and microbial interactions.</p><h4><span><strong>Implications for Gut Microbiome Research</strong></span></h4><p>N-glycans represent a potential class of <strong>prebiotic substrates</strong> that can influence gut microbiota composition and activity.</p><p>Key findings suggest:</p><ul><li>Structural diversity of glycans affects <strong>microbial utilization patterns</strong></li><li>More complex glycans may promote <strong>greater microbiome diversity</strong></li><li>Specific glycan structures may selectively stimulate beneficial microbes</li></ul><p>This has led to growing interest in:</p><ul><li><strong>Synbiotic strategies</strong>, combining microbes with preferred substrates</li><li>Tailored dietary interventions to enhance <strong>metabolic outputs</strong>, such as short-chain fatty acids</li></ul><h4><span><strong>Methodological Considerations</strong></span></h4><p>A critical insight from this work is the importance of understanding <strong>analytical trade-offs</strong>:</p><ul><li>MALDI-TOF MS provides broader detection of glycan structures</li><li>LC-MS approaches offer greater reproducibility</li></ul><p>No single technique is universally optimal; instead, method selection should be guided by the specific research question.</p><h4><span><strong>Conclusion</strong></span></h4><p>N-glycans in dietary proteins represent a complex and biologically significant class of biomolecules with implications spanning nutrition, microbiology, and disease research. Advances in analytical methodologies continue to improve our ability to characterize these structures, despite challenges related to low abundance and structural diversity.</p><p>A deeper understanding of N-glycan composition and function may enable the development of targeted nutritional strategies and microbiome-based therapeutics, highlighting the growing importance of glycomics in modern life sciences.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

N‑Glycans, Whey Protein, and the Gut Microbiome: Mass Spec Insights with Matthew Bolino

<div><div><div><p><strong>Our immune system is incredibly powerful: among other things, it can recognize and destroy cancer cells. But tumors can be just as effective at avoiding detection – they build “invisibility shields” to protect themselves from attack.</strong></p></div></div><div><p>One breakthrough in cancer therapy has been immune checkpoint inhibitors (ICIs), drugs that reactivate immune T cells and help them fight tumors again. However, only about 20–50% of patients respond well to this treatment. Researchers are therefore seeking alternative therapeutic strategies. A small and well-known molecule called adenosine plays a key role in these efforts.</p><p>When tumor cells are stressed or dying, they release ATP, which is normally a signal that something is wrong in the tissue. But in the tumor microenvironment, ATP gets rapidly broken down by two enzymes, CD39 and CD73. Released adenosine acts like a chemical “calm-down” signal, binds to immune cells (T cells, NK cells, and others), and tells them to slow down, reducing their ability to kill cancer cells. Targeting CD73 therefore represents a promising strategy for developing new cancer treatments.</p></div><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg" alt="IOCB Prague: Development of potent inhibitors to boost the immune system's ability to fight cancer" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_UOCHB_Nove_latky_mohou_podporit_imunitni_system_v_boji_s_rakovinou_88c5e82cd5.jpeg 245w," sizes="100vw" width="661" height="363"></p><p>At IOCB Prague, interdisciplinary teams led by Jan Řezáč, Jan Konvalinka, and Michal Hocek used a newly developed high-throughput screening method to test over 5,000 compounds, identifying two ribonucleoside derivatives as promising CD73 inhibitors.</p><p>The scientists then improved the compounds’ activity by carefully modifying the ribonucleoside scaffold with bulky (het)aryl groups. Further optimization improved the pharmacokinetic properties of these compounds, yielding inhibitors with low clearance, long half-life, high solubility, and strong selectivity over related enzymes such as CD39.</p><p>In cellular experiments, the compounds reduced adenosine production in cancer cells, restored T cell activation, and showed no toxicity toward human fibroblasts. The most active compound showed a single-digit picomolar inhibition constant (Ki).</p><p>These findings establish a strong foundation for further in vivo efficacy and combination studies, which will explore the therapeutic potential of this novel inhibitor class.</p><blockquote><h4><strong>The Original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707"><strong>Potent Competitive Inhibitors of Ecto-5′-nucleotidase (CD73) based on 6-(Het)aryl-7-deazapurine Ribonucleoside 5′-O-Bisphosphonates</strong></a></h4><p>Ugnė Šinkevičiu̅tė, Magdalena Šímová, Radek Staník, Lenka Poštová Slavětínská, Kristýna Blažková, Pavel Šácha, Martin Lepšík, Jan Řezáč, Jan Konvalinka, Tereza Ormsby, Michal Tichý, Michal Hocek</p><p><i><span><strong>ACS Pharmacol. Transl. Sci.</strong></span></i><strong> </strong><span><strong>2026, 9, 1, 191–213</strong></span></p><p><a target="_blank" rel="noopener noreferrer" href="https://pubs.acs.org/doi/10.1021/acsptsci.5c00707">https://pubs.acs.org/doi/10.1021/acsptsci.5c00707</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><p>CD73 generates immunosuppressive adenosine in the tumor microenvironment and is a promising target for cancer immunotherapy. We have designed and systematically studied diverse 2-substituted 7-deazapurine ribonucleoside 5′-<i>O</i>-bisphosphonates bearing a variety of (het)aryl groups at position 6 and discovered their highly potent and selective CD73 inhibition activity. The most active compounds (with single-digit picomolar <i>K</i><sub>i</sub>) contained bicyclic (het)aryl groups at position 6 in combination with chlorine at position 2. Further optimization of pharmacokinetic properties identified inhibitors with low clearance, long half-life, high solubility, and excellent selectivity over CD39 and NTPDase3. They effectively suppressed adenosine formation in MDA-MB-231 cells, rescued CD8<sup>+</sup> T cell activation, and were nontoxic to human fibroblasts. Overall, their profile compares favorably with <strong>AB680</strong>, a CD73 inhibitor currently in phase I/II clinical trials.</p></div>

Development of potent inhibitors to boost the immune system's ability to fight cancer

Article

Video

Scientists

Environment

Scientific article

Interview

Science and research

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. 

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Agilent Technologies

Thermo Fisher Scientific

SelectScience

Shimadzu Corporation

SCIEX

Plasmion

<p><strong>The hunt goes on, let's find the needle in the haystack:</strong></p><p>Join us for an insightful webinar where we delve into the world of chemometrics to enhance your data interpretation skills. Learn how to select the appropriate statistical tools to make sense of your data and identify features of interest by visualizing trends and changes using various clustering and grouping approaches. We will also cover the construction of class prediction models to differentiate between sample cohorts effectively.</p><p>Finally, gain a deeper understanding of your findings by mapping them onto relevant metabolomic pathways, providing essential context for your research.</p><blockquote><p><strong>Presenter:</strong> Hannah Florance (Application Specialist LC/MS, Agilent Technologies)</p><p>Hannah has had multiple roles in the life sciences, starting as a protein chemist, before moving into proteomics and then metabolomics. A major part of her time working in academia involved running LC and GCMS core facilities supporting projects ranging from synthetic biology to cancer research. She is currently an LCMS applications specialist for Agilent.<br><br><strong>Presenter:</strong> Shaun Reeksting (Application Specialist LC/MS, Agilent Technologies)</p><p>Shaun completed his PhD in Biochemistry, specializing in molecular parasitology a focus in metabolomics. Following his doctoral studies, he worked in accredited industry laboratories and academia core-facilities before joining Agilent Technologies as an LC/MS Application Engineer.</p><p>In this role, Shaun focuses on environmental small molecule applications using LC-QTOF, with a strong emphasis on software tools and data interpretation.</p></blockquote>

Agilent Technologies: MassHunter Masterclass Months

Finding the Needle in the Haystack Part II; All Things Chemometric

Join us for an insightful webinar where we delve into the world of chemometrics to enhance your data interpretation skills.

All Things Chemometric

<p><strong>In our last session, we will tackle compliance as we will delve into the critical aspects of compliance and its significance for your laboratory.</strong></p><p>Discover what compliance entails and why it is essential for maintaining the integrity and reliability of your lab’s operations. We will explore the various configurations available to meet your specific regulatory requirements, ensuring you have the necessary tools and knowledge to stay compliant.</p><p>Additionally, gain valuable insights into content management, audit trails, and applications that streamline your compliance processes, making your lab more efficient and secure.</p><p>Don’t miss this opportunity to enhance your understanding of working in a regulated environment and ensure your lab’s success.</p><blockquote><p><strong>Presenter:</strong> &nbsp;Christian Hegmanns (Application Specialist LC/MS, Agilent Technologies, Waldbronn, Germany.)</p><p>Christian Hegmanns is a state-certified food chemist and works at Agilent as an LC/MS application specialist.</p><p>With over 10 years of experience in the field of instrumental analysis, Christian develops customer-oriented solutions for a variety of applications with a focus on food analysis.</p></blockquote>

MassHunter Compliance – Working in a Regulated Environment

We will tackle compliance as we will delve into the critical aspects of compliance and its significance for your laboratory.

<p><strong>Metabolic Profiling through Direct Breath Analysis:</strong></p><p>We demonstrate an easy extension of conventional capabilities for the SICRIT® ionization source, coupled to a high-resolution MS instrument, through a metabolomic-based breath analysis and how groups of target masses can be isolated and analyzed for potential biomarker identification. Additionally, we can see the sensitivity and broad ionization capabilities of the source through a comparison of different subjects, where the subtle differences in everyone’s metabolic profile is given by the spectral distribution of metabolite density.</p><p><strong>Metabolomic CSI: HRMS Lipidomic Profiling of Fingerprints using TD-SICRIT®-MS and Bioinformatics Pipeline</strong></p><p>We demonstrate the capabilities of the TD-SICRIT®-MS and how they can be utilized in the world of metabolomics and lipidomics, with the full potential of such a study being realized through the combination of chemistry and computation.</p><p>Don't miss this opportunity to enhance your understanding of SICRIT® technology and its applications!</p>

Plasmion: Exploring Metabolomics With SICRIT®

Exploring Metabolomics With SICRIT®

Explore the diverse application possibilities of SICRIT® ionization source in the field of metabolomics.

<p><strong>Therapeutic synthetic oligonucleotides face unique analytical challenges in late-stage development. Meeting stringent regulatory requirements demands highly specific and sensitive methods like LC-MS. However, typical QC analysts struggle with the complexity of purity, assay and impurity profiling due to limitations in current chromatography and mass spectrometry data systems.</strong></p><p>This webinar will explore a paradigm shift in software that streamlines the analytical workflow while maintaining data integrity and compliance. Our expert speakers will also discuss how to apply the Oligo Analysis Accelerator for OpenLabs CDS to your oligonucleotide therapeutic testing, helping you to optimize synthesis and purification.</p><p><strong>Attend this webinar to:</strong></p><ul><li>Discover how fit-for-purpose software for LC-MS analysis in QC lot release can save time and enhance quality</li><li>Understand the fundamentals of ion-pair reversed phase LC-MS for oligonucleotides</li><li>Discover how to use single quadrupole detector for impurity profiling of anti-sense oligonucleotides</li></ul><blockquote><p><strong>Presenter: </strong>Charlotte Lekieffre, PhD (Biopharma Application Specialist, Agilent Technologies)</p><p>Charlotte holds a PhD from the Ecole Polytechnique Fédérale de Lausanne and has 10 years' experience in developing analytical workflows for mass spectrometry. She now brings her expertise to Agilent's customers as an LCMS Application Specialist in the BioPharma sector.</p><p><strong>Presenter: </strong>Kevin Koelliker (Lab Informatics Application Engineer at Agilent Technologies)</p><p>Kevin is a Lab Informatics Application Engineer for Agilent Technologies. He studied Chemistry and Business informatics, and he worked as a Lab Technician, and as a Field Service Engineer before joining Agilent. Combined he has more than 15 Years of Experience in the analytical laboratory and therefore met already multiple different workflows. He works together with the Lab Informatics Product Specialists to demonstrate the Power of OpenLab, and to customize it to meet the needs of our Customers.</p></blockquote>

Technology Networks: Mastering QC Oligonucleotide LC-MS in GMP Labs

Mastering QC Oligonucleotide LC-MS in GMP Labs

This webinar will explore a paradigm shift in software that streamlines the analytical workflow while maintaining data integrity and compliance.

<p><strong>In this webinar, Novartis will show how they are digitalizing and fully automating systems across large molecule R&amp;D. By integrating liquid handling systems, mass spectrometers, and the Genedata Biopharma platform, Novartis has implemented a ‘full-circle’ mass spectrometry (MS) workflow automation for standardized analyses. Their automated MS workflow includes analytics requests by laboratory scientists, barcoding, sample preparation, mass spectrometry, data analysis, and reporting. Automating repetitive tasks increases efficiency and allows scientists to focus on more complex projects and advanced sample analytics.</strong></p><p>Join Felix Stemmer, Senior Scientist II, and Martin Jockel, Senior Expert in Data Science, from Novartis as they illustrate how they are streamlining processes and accelerating operations.</p><p><strong>Key learning objectives</strong></p><ul><li>Discover how Novartis is automating complex MS-based workflows in biopharma R&amp;D</li><li>Learn how Novartis has implemented a ‘full-circle’ MS analytics platform, integrating high quality MS data into an enterprise-level biotherapeutics discovery platform</li><li>Hear how Novartis scientists significantly increased research efficiency by using MS analytics workflows</li></ul><p><strong>Who should attend?</strong></p><ul><li>Biopharmaceutical analytical scientists, laboratory leaders, and directors who are looking to develop and automate MS-based analytics in biotherapeutic R&amp;D.</li><li>IT professionals, automation architects, and engineers looking to support organizational-level data platforms for digitalization of complex, multidimensional data streams in biologics discovery workflows.</li></ul><p><strong>Certificate of attendance</strong></p><p>All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.</p><blockquote><p><strong>Presenter:</strong> Martin Jockel (Senior Expert I Data Science, Novartis)</p><p>Martin Jockel, a bioinformatics graduate from the Technical University of Applied Sciences in Bingen, has worked for Novartis for the past 12 years. His proficiency in crafting custom software solutions has enhanced laboratories’ capabilities in data storage and visualization, leading to optimized workflows and increased efficiency.</p><p>In recent years, Jockel has further broadened his scope to include lab automation, ensuring these processes are integrated into Novartis’ technical ecosystem. For the past three years, he has been contributing to the Genedata project at Novartis as a developer and as the Scrum Master for the Technical Team.</p><p><strong>Presenter:</strong> Felix Stemmer (Senior Scientist II, Novartis)</p><p>Felix Stemmer has a background in bioengineering from the Karlsruhe Institute of Technology where his passion for lab automation began. Now working at Novartis, Stemmer is currently working on a collaborative project with Genedata, integrating liquid handling systems and analytical instruments into Genedata’s respective software.</p><p>Before joining Novartis, Stemmer worked on a series of automation projects including miniaturizing downstream processing and CHO and HEK upstream processing, highlighting his extensive experience in automation.</p></blockquote>

SelectScience: Full-Circle MS Workflow Automation at Novartis

Full-Circle MS Workflow Automation at Novartis

Novartis will show how they are digitalizing and fully automating systems across large molecule R&D.

<p><strong>With the need for risk assessment and testing plans looming on the horizon, join us to learn about the challenges of low-level nitrosamine detection for both LCMS and GCMS applications.</strong></p><p>We will explore the pressing questions of coming regulation, including guidance on NDSRIs, the differing use cases of the 4 Procedures of USP &lt;1469&gt; and how Shimadzu can be your partner in creating solutions to meet these requirements.</p><p>As you prepare for the August 1, 2025 deadline, whether your needs will be nitrosamine discovery with LCMS-QTOF or high-sensitivity QC monitoring with headspace GC-MS/MS, Shimadzu has the hardware and applications to help you succeed.</p><p>We will host a Q&amp;A session after the presentation to address any questions or comments.</p><blockquote><p><strong>Presenter:</strong> Brian Domanski (Strategic Collaboration Scientist, Shimadzu Scientific Instruments)</p><p>Brian has over 10 years working to provide LC and SFC solutions for Pharma, as well as experience with a wide range of chromatography techniques including RP, NP, HILIC, IEX, SEC/GPC, and IC. His focus also includes scalable Informatics and Data Integrity solutions.</p></blockquote>

Shimadzu: Are you Nitrosamine Ready? Solutions for Nitrosamine Analysis

Are you Nitrosamine Ready? Solutions for Nitrosamine Analysis

Join us to learn about the challenges of low-level nitrosamine detection for both LCMS and GCMS applications.

Solutions for Nitrosamine Analysis by LCMS and GCMS

<p><strong>Innovating for the future with cutting-edge solutions</strong></p><p><strong>Given the speed and scale of progress with Artificial Intelligence (AI) in today’s world, researchers and professionals across various scientific fields from the Danaher group of companies have stepped up in the game of AI and advanced technology to seek breakthrough solutions to age-old problems.</strong></p><h3><strong>Agenda</strong></h3><h5><strong>Introduction to Danaher</strong></h5><h5><strong>3D biology and the paradigm shift in next generation drug discovery</strong></h5><ul><li>Presented by Molecular Device</li></ul><h5><strong>AIVIA - introduction to AI based image analysis</strong></h5><ul><li>Presented by Leica Microsystems</li></ul><h5><strong>Analytical advances in the characterization of mRNA</strong></h5><ul><li>Presented by Phenomenex</li></ul><h5><strong>Unlocking the power of data with IDBS</strong></h5><ul><li>Presented by IDBS</li></ul><h5><strong>The power of AI: from planning and the lab to success in life sciences</strong></h5><ul><li>Presented by Abcam</li></ul><h5><strong>Practical approaches to EV characterization and purification: leveraging nano Flow Cytometry and ultracentrifugation for clinical and commercial success</strong></h5><ul><li>Presented by Beckman Coulter Life Sciences</li></ul><h5><strong>AI-MS/MS-AI mass spectrometry application with AI</strong></h5><ul><li>Presented by SCIEX</li></ul><h5><strong>Work smarter, not harder: emerging lessons on data in biopharma R&amp;D</strong></h5><ul><li>Presented by Genedata</li></ul><h5><strong>In silico process development with mechanistic chromatography modelling</strong></h5><ul><li>Presented by Cytiva</li></ul><h5><strong>CRISPR meets NGS: the powerful duo for drug discovery</strong></h5><ul><li>Presented by IDT</li></ul><h3><strong>Presenter:</strong></h3><ul><li>Gokhale, Aarti Arun, Ph.D (Sr Manager, Gene Reading, APAC, IDT)</li><li>Teo Chong Kok Ph.D (Scientific Account Manager, Genedata)</li><li>Edward Lim (General Manager, SEA, Beckman Coulter Life Sciences)</li><li>Taryn Guinan, Ph.D (Sr Applications Specialist, ANZ, Leica Microsystem)</li><li>Edward Wong, Ph.D (Sr Manager, Gene Writing &amp; Editing, APAC, IDT)</li><li>Stephan Waldert, Ph.D (Director, Data Science &amp; AI, Abcam)</li><li>Manish Manakchand (Commercial Director, Asia, IDBS)</li><li>Namrata Saxena (Technical Manager, Phenomenex)</li><li>Hans Lin (Field Application &amp; Market Development Specialist, SCIEX)</li><li>Mok Wei Chuan (Go Silico Sales Specialist, APAC, Cytiva)</li><li>Minho Tak, Ph.D (Sr Application Scientist, JAPAC, Molecular Device)</li></ul>

SCIEX: AI and technology advancements from Danaher

AI and technology advancements from Danaher

In this live webinar, let’s explore how Danaher group of companies leverage AI and technologies in providing advanced solutions.

<p><strong>The technologies presented will be CE and LC-MS.</strong></p><p><i>The presentations will also be available on demand after the virtual event.</i></p><h3><strong>(Day 2): Gene therapy, vaccines and oligonucleotides</strong></h3><h5><strong>10:00–10:10 Welcome and introduction</strong></h5><ul><li>Steve Lock, SCIEX, UK</li></ul><h5><strong>10:10–10:35 The latest developments in plasmid analysis by CE</strong></h5><ul><li>Luiza Chrojan / Ryan Hylands, Pharmaron, UK</li></ul><h5><strong>10:35–11:00 Pure and simple: understanding LNP analytics for better mRNA-based drugs</strong></h5><ul><li>Adam Crowe, Cytiva, Canada</li></ul><h5><strong>11:00–11:25 Tips and tricks to speed up CE-SDS analysis</strong></h5><ul><li>Marcus Heinl, SCIEX, Germany</li></ul><h5><strong>11:25–11:35</strong> Break</h5><h5><strong>11:35–12:00 Applying CE to viral vector analysis of process samples</strong></h5><ul><li>Juliette Laigle / Yolande Masson, Yposkesi, France [NEW SPEAKERS]</li></ul><h5><strong>12:00–12:25 Exploring mRNA mapping and aggregation analyses for mRNA characterization</strong></h5><ul><li>Lucia Geis Asteggiante, Phenomenex, Italy</li></ul><h5><strong>12:25–12:50 After the experiment: electronic lab execution as standard</strong></h5><ul><li>Marc Smith, IDBS, UK [NEW SPEAKER]</li></ul><h5><strong>12:50–13:00</strong> Wrap-up and Q&amp;A</h5><blockquote><p><strong>Your host: </strong>Steve Lock, PhD (Senior Marketing and Market Development Manager, Biopharma, EMEAI, SCIEX)<br><br>Steve obtained his PhD in Physical Organic Chemistry from the University College of Swansea in 1993 and is a chartered chemist and a member of the Royal Society of Chemistry. He has worked for SCIEX in various technical roles for over 20 years and has presented at over 80 international meetings around the world. He currently works closely with customers in the biopharmaceutical industry. Steve is also currently an Adjunct Professor at the University of Pannonia.</p></blockquote>

2024 SCIEX Biopharma meeting (Day 2): Gene therapy, vaccines and oligonucleotides

This online event has been designed for our customers and brings  together opinion leaders, top scientists and industry innovators.

SCIEX Biopharma: Gene therapy, vaccines and oligonucleotides

<p><strong>This presentation provides an overview of a study comparing mouse models to human data, focusing on pre-symptomatic stages to analyze the prefrontal cortex. The TDP-43D3 mice, which can live up to 120 weeks, and the more aggressive C9R72 mouse model were used.</strong></p><p>The study identified sex-specific differences in both mice and humans. Proteomics analysis detected an average of 2,344 proteins per sample, revealing significant deregulations similar to those found in transcriptomics. Common pathways, such as the MAPK pathway, were consistently observed across various analyses, from transcriptomics to proteomics. The study employed a biologically motivated approach to identify valid interactors and validated findings in the lab using mouse models.</p><p>Phosphoproteomics and quadruplets analysis further identified important candidates like sequestosome, linked to autophagy. Synaptic and cytoskeletal dysfunctions were noted in both mouse and human samples. Cell type deconvolution based on transcriptomics data was also performed. The results consistently highlighted the MAPK pathway and synaptic compartments, guiding future validation steps. The findings have been recently published for further reference.</p><h5>Learning points:</h5><ul><li id="isPasted"><strong>Pre-symptomatic Analysis in ALS Research&nbsp;</strong></li><li><strong>Sex-specific Differences and Pathway Consistency &nbsp;&nbsp;</strong></li><li><strong>Validation and Functional Implications &nbsp;</strong></li></ul><h5>Who should attend:</h5><ul><li>Neuroscientists and Researchers: Those focused on ALS and other neurodegenerative diseases would gain insights into early disease mechanisms and potential therapeutic targets.&nbsp;</li><li>Pharmaceutical and Biotech Companies: Entities involved in drug development for neurodegenerative diseases might benefit from the identified pathways and molecular targets, aiding in the development of new therapies.&nbsp;</li></ul><div dir=""><div><div><strong>Presenter:</strong> Dr. rer. nat. Lucas Caldi Gomes (Lingor Lab, Department of Neurology, TUM)</div></div></div>

Thermo Fisher Scientific: Multiomic profile integration reveals early disease signatures of Amyotrophic lateral sclerosis

Multiomic profile integration reveals early disease signatures of Amyotrophic lateral sclerosis

This presentation provides an overview of a study comparing mouse models to human data, focusing on pre-symptomatic stages to analyze the prefrontal cortex.

Multiomic profile integration reveals early disease

<p><strong>The complete Solution for Food Analysis: Presented by Retsch, CEM, Shimadzu and Eltra</strong></p><p>Accurate and rapid food analysis is becoming increasingly important as regulations become stricter and consumers become more demanding. This expert day on food analysis will give you a comprehensive overview of the optimal steps from sample preparation to analysis, familiarize you with modern methods and bring you up to date.</p><p>Registration is free of charge and without obligation.</p><div><div><div><div><div><h3><strong>Heavy metals and pesticides in highly processed&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</strong></h3><p>In the third part of the webinar series the focus is on analytics. Each step of food processing presents a source of contamination, which is why highly processed foods (ultra-processed foods (UPF)) should be viewed critically.</p><p>Heavy metals are analyzed using ICP-MS and pesticides using GCMS/MS and SFC-LCMS/MS. You have the opportunity to get in touch with device experts and discuss your questions.</p></div></div><p><strong>In this webinar, you will learn more about:</strong></p><ul><li>How to measure pesticides in difficult samples using LC-MS/MS and SFC-MS/MS</li><li>Determination of pesticides in food samples using GC-MS/MS with hydrogen as carrier gas</li><li>Challenges and solutions for heavy metal analysis</li><li>How much heavy metals are lurking in trend food products?</li></ul><p><strong>Presenters:</strong> Uwe Oppermann, Stéphane Moreau, Waldemar Weber and Johannes Hesper</p></div></div></div>

Heavy metals and pesticides in highly processed

Heavy metals are analyzed using ICP-MS and pesticides using GCMS/MS and SFC-LCMS/MS. 

LCMS webinars focusing on LC/MS - page 42